Stock Ticker

  • Loading stock data...

Shareholder Alert: Ingredion Inc (NYSE:INGR), Nautilus, Inc. (NYSE:NLS), Durata Therapeutics Inc (NASDAQ:DRTX)

Boston, MA 05/16/2014 (wallstreetpr) – Ingredion Inc (NYSE:INGR) launched an online calculator to help confectionery manufacturers to see how they can make big financial savings by using its new starch ingredient called PERFECTAGEL MPT. The company is offering the ingredient as a replacement for gelatin. Confectionary manufacturing market can save up to $0.5 million per year by replacing gelatin with PERFECTAGEL MPT. In addition to the cost, the ingredient also leads to longer shelf life for the products. Ingredion Inc (NYSE:INGR) expects its online calculate to help manufacturers see more sense in its claims about PERFECTAGEL MPT. The new online calculation service comes at a time when the company is facing intense competition that recently caused it in 1Q2014. The trouble in the quarter emanated from North America where in addition to competition, harsh winter weather impacted sales.

Nautilus, Inc. (NYSE:NLS) announced that its executive members including CEO Bruce M. Cazenave, CFO Sid Nayar and COO William B. McMahon will present at the 15th Annual B. Riley Investor Conference in California. The event will take place at Loews Hotel in Santa Monica between May 19 and 21. The presentation comes on the back of a promise by the company to its investors that it expects strong sales and positive performance in 2014. The company recently raised sales growth where sales jumped 21 percent on a year-over-year basis to $59.2 million. That followed a 13 percent increase in sales in 2013. Nautilus, Inc. (NYSE:NLS) reported a net income of $5.7 million or 18 cents from continuing operations. Shares of the company are up 33.81 percent year-to-date.

Pharmaceutical company Durata Therapeutics Inc (NASDAQ:DRTX) had its “buy” rating reiterated by analysts at Summer Street. The analyst also planted a 12-month price target of $24 on the stock. On the average, the stock carries consensus “buy” rating and average price target of $18. The company reported it most recent quarter on May 8, whereby it realized a loss of 62 cents, but succeeded to beat Wall Street estimate of 64 cents. Shares of Durata Therapeutics Inc (NASDAQ:DRTX) are up 1.91 since the beginning of 2014.

Published by Duncan Oleinic

Duncan Oleinic is from New Yourk. After graduating with a degree in physics, he began his career as an analyst in a broking firm. Through this experience he was able to advance to the role of correspondent for a U.S based financial news provider, where he worked from 2001 to 2007. He subsequently joined a merchant banking firm as a financial analyst focused on valuing unlisted companies in the sub-continent. Over the course of his two years here, he performed valuations of several media companies which were later acquired by peers.

Recent Stories

SignUp Now For Our Featured Newsletter